Dataset from Phase I, Open-label, Single-dose, Sequential, Randomized, Crossover Study of Acalabrutinib Suspension Delivered Via Nasogastric Tube in Healthy Subjects to Evaluate Relative Bioavailability and Proton-pump Inhibitor (Rabeprazole) Effect

This study is being conducted to support the clinical development of acalabrutinib in
patients who are unable to swallow capsule and require nasogastric (NG) tube placement.